Mind Medicine Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), a US-based biotech company developing psychedelic-inspired therapies, announced on Friday that it has started Phase 2a proof-of-concept (PoC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD).

The company has activated its first site and patient enrolment is expected to commence immediately.

The Phase 2a PoC trial will be conducted in partnership with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands, and is aimed at assessing the therapeutic utility of repeated low doses of LSD. This is a multicentre, randomised, double-blind, placebo-controlled Phase 2a trial assessing the safety and efficacy of low-dose LSD as treatment for ADHD in adults. The trial is planning to enrol a total of 52 patients that will receive 20µg of LSD (every (dose schedule) or placebo for six weeks (twice a week on a 3/4-day schedule [± 1 day]). Dr. Matthias Liechti, at University Hospital Basel, Switzerland and Dr. Kim Kuypers at Maastricht University, the Netherlands are to head the trial.